Acabrunat Acalabrutinib 100mg Capsule Natco

Acabrunat Acalabrutinib 100mg Capsule Natco Specification

Salt Composition
Acalabrutinib 100mg

Dosage Form
Capsule

Indication
Treatment of mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL)

Feature
Bruton Tyrosine Kinase (BTK) inhibitor, targeted cancer therapy

Ingredients
Acalabrutinib and pharmaceutical excipients

Application
Oral use in oncology

Physical Color/Texture
Off-white to light yellow, capsule form

Fermentation Smell
Odorless

Storage Instructions
Store below 30C in a dry place, protect from light

Shelf Life
24 months

Strength
100mg per capsule

Patient Population
Adults

Molecular Formula
C26H23N7O2

Administration Route
Oral

ATC Code
L01EL04

Pack Size
30 capsules per bottle

Available Packaging
Sealed bottle with product leaflet

Compatibility
Not to be used with strong CYP3A inhibitors or inducers

Prescription Status
Prescription only (Rx)

Therapeutic Class
Antineoplastic agent

Warning
To be used under oncologist supervision only

Brand Name
Acabrunat

About Acabrunat Acalabrutinib 100mg Capsule Natco

Experience grandiose value and lustrous savings with Acabrunat Acalabrutinib 100mg Capsule, a lofty innovation in targeted cancer therapy by Natco. Designed for adult patients, Acabrunat offers competitive pricing, supporting affordability while never compromising on efficacy or safety. Each sealed bottle contains 30 off-white to light yellow odorless capsules, formulated as a Bruton Tyrosine Kinase (BTK) inhibitor to provide precise antineoplastic action against mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). Prescription-only and meant strictly for oncologist supervision, Acabrunat ensures distinguished quality, robust shelf life, and secure packaging, making it an exceptional choice for dealers, distributors, exporters, and wholesalers across India.

Superior Advantages and Application Method

Acabrunat Acalabrutinib 100mg Capsule offers a remarkable advantage as a targeted therapy for mantle cell lymphoma and chronic lymphocytic leukemia. Its primary competitive edge lies in its molecular precision and cost-effectiveness. The capsule is administered orally, ensuring patient convenience and adherence. As a prescription-only treatment for adults, its reliable efficacy under oncologist supervision underscores its preference among healthcare professionals, making it an outstanding solution for patients in need of advanced, supportive oncology care.

Certifications, Export Markets, and Supply Logistics

Acabrunat Acalabrutinib 100mg Capsule is manufactured following strict certifications that assure quality and safety. With its main export markets across various regions, the product is frequently handed over to trusted partners worldwide. Thanks to a robust supply chain, goods are efficiently freighted and handed over punctually. These streamlined logistics ensure timely and safe delivery, reinforcing the brands credibility among global exporters, dealers, and distributors.

FAQs of Acabrunat Acalabrutinib 100mg Capsule Natco:

Q: How should Acabrunat Acalabrutinib 100mg Capsule be administered?

A: Acabrunat should be taken orally as directed by an oncologist. The recommended dosage and frequency depend on the individuals treatment plan, and it should never be self-administered without professional supervision.

Q: What are the primary benefits of choosing Acabrunat over alternatives?

A: Acabrunat provides competitive pricing, exceptional value, and targeted therapy, ensuring precise cancer cell inhibition. Its grandiose efficacy and quality guarantees savings while delivering reliable results in mantle cell lymphoma and chronic lymphocytic leukemia treatment.

Q: When can Acabrunat be prescribed, and for whom is it suitable?

A: Acabrunat is prescribed exclusively for adult patients diagnosed with mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL) under the supervision of an oncologist, following a confirmed diagnosis.

Q: Where should Acabrunat Acalabrutinib capsules be stored for safety and quality maintenance?

A: The capsules must be stored below 30C in a dry place, protected from light, and kept in a sealed bottle as specified in the product leaflet to ensure optimal efficacy and shelf life.

Q: What precautions are necessary before starting therapy with Acabrunat?

A: Patients should avoid strong CYP3A inhibitors or inducers and strictly adhere to the oncologists instructions. Detailed consultation and evaluation by a healthcare provider are essential before starting Acabrunat therapy.

Tell us about your requirement